Jun 26, 2023 · Eli Lilly’s Mounjaro, cleared for type 2 diabetes and awaiting FDA approval for weight loss, targets both GLP-1 and a hormone called GIP, and has produced weight loss of 21 to 23%....

Aug 27, 2024 · Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company says will “significantly” expand supply...

1 day ago · Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than expected. The company ...

1 day ago · Eli Lilly and Company (NYSE: LLY) has announced that it will release late-stage data on its next-generation weight loss drug, retatrutide, in 2025, earlier than initially expected. The drug, which is being studied for the treatment of obesity, has shown promising results in early trials, and the company is now poised to accelerate its ...

Nov 8, 2023 · Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight.

Oct 15, 2023 · In a co-primary endpoint, following the lead-in period, participants taking tirzepatide achieved an additional 21.1% mean weight loss. In a secondary endpoint, participants achieved a total mean weight loss of 26.6% (29.2 kg or 64.4 lb.) from study entry over 84 weeks.

INDIANAPOLIS, April 28, 2022 /PRNewswire/ -- Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli Lilly and Company's (NYSE: LLY) SURMOUNT-1 clinical trial, with participants losing up to 22.5% (52 lb. or 24 kg) of their body weight for the efficacy estimand i ...

Dec 6, 2023 · Drug manufacturer Eli Lilly announced Tuesday that its flagship weight loss medication, Zepbound, is now available for patient use. Tirzepatide, its active ingredient, had been approved by the...

Nov 8, 2023 · The Food and Drug Administration on Wednesday approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that was shown in clinical trials to help people lose up to 52 pounds in 16...

Nov 9, 2023 · In clinical trials, Zepbound helped people lose, on average, 52 pounds, nearly rivaling the weight loss results achieved with bariatric surgery, according to Dr. Christopher McGowan, a...